Menagen Pharmaceutical Industries has unveiled a groundbreaking pharmaceutical plant in Oman’s Rusayl Industrial Area, marking a first in the Middle East for its dedicated focus on producing medications for rare diseases and various cancers.
The facility, built with an investment of over OMR 20 million, is designed to manufacture treatments for genetic disorders, metabolic diseases, hereditary blood conditions, kidney diseases, and multiple cancer types. Its establishment is a pivotal step in addressing the healthcare needs of patients within Oman and the wider region.
A notable feature of the plant is its development and innovation center, the first of its kind in the Middle East. This center is poised to conduct preliminary studies and research in collaboration with Sultan Qaboos University’s Centre for Medical Research, aiming to propel advancements in drug discovery and development.
Through this initiative, Menagen Pharmaceutical Industries aspires to revolutionize the pharmaceutical landscape by providing innovative, life-saving medications, thereby enhancing the quality of life and health security across the Middle East and North Africa
